— Acasti Pharma Inc. (NASDAQ: ACST) reported Q3 2020 net loss of CAD15.7 million, or CAD0.18 per share, compared to net loss of CAD4.6 million, or CAD0.07 per share, last year.
— Loss from operating activities was CAD7.9 million compared to a loss of CAD10.7 million last year.
— R&D expenses before depreciation, amortization and stock-based compensation expenses were CAD4.2 million compared to CAD8.8 million last year.
— General and administrative expenses before stock-based compensation expenses were CAD1.6 million versus CAD0.76 million last year.
— Sales and marketing expenses before stock-based compensation expenses were CAD0.74 million compared to CAD0.13 million last year.
— Cash and cash equivalents and marketable securities totaled CAD25.7 million as of December 31, 2019.
— ACST shares gained 0.69% immediately following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Infographic: Highlights of Halliburton’s (HAL) Q1 2024 earnings results
Energy giant Halliburton Company (NYSE: HAL) Tuesday announced financial results for the first quarter of 2024, reporting lower earnings and a modest increase in revenues. First-quarter revenue edged up 2%
UPS Earnings: United Parcel Service Q1 2024 revenue and earnings fall
United Parcel Service, Inc. (NYSE: UPS) Tuesday reported lower revenues and adjusted profit for the first quarter of 2024. The company reaffirmed its full-year 2024 guidance. On an adjusted basis,
Key highlights from Philip Morris’ (PM) Q1 2024 earnings results
Philip Morris International Inc. (NYSE: PM) reported first quarter 2024 earnings results today. Net revenues increased 9.7% year-over-year to $8.8 billion. Organic revenue growth was 11%. Net earnings attributable to
